

AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of claims

1. (Currently amended) A method for promoting differentiation of a neural stem cell or a neural progenitor cell into a differentiated neural cell, comprising inhibiting ATF5 in the cell with a specific inhibitor of ATF5 in an amount effective to decrease the activity of ATF5 in the cell and promote neural differentiation of the cell.
2. (Previously presented) The method of claim 1, further comprising the step of contacting the neural stem cell or neural progenitor cell with at least one neurotrophic factor.
3. (Previously presented) The method of claim 1, wherein the differentiated neural cell is selected from the group consisting of an astrocyte, an astroglial cell, a neuron, an oligodendrocyte, an oligodendroglial cell, and a Schwann cell.
4. (Previously presented) The method of claim 1, wherein the differentiated neural cell expresses enhanced green fluorescent protein (eGFP).
5. (Currently amended) The method of claim 1, ~~wherein ATF5 is inhibited in the neural stem cell or neural progenitor cell by contacting the cell with an inhibitor of ATF5, wherein the~~ ATF5 inhibitor is selected from the group consisting of an ATF5 antibody, siRNA, dominant

negative ATF5, and antisense RNA.

6. (Previously presented) The method of claim 1, wherein ATF5 is inhibited in the neural stem cell or neural progenitor cell in vivo in a subject.

7. (Previously presented) The method of claim 1, wherein ATF5 is inhibited in the neural stem cell or neural progenitor cell in vitro.

8. (Previously presented) The method of claim 7, further comprising the step of transplanting the differentiated neural cell into a subject.

9. (Previously presented) The method of claim 8, wherein the subject is an embryo.

10. (Previously presented) The method of claim 8, wherein the subject is a human.

11. (Previously presented) The method of claim 8, wherein the subject has nervous tissue degeneration.

12. (Currently amended) An isolated differentiated neural cell produced by the method of claim 1.

13. (Previously presented) The differentiated neural cell of claim 12, which expresses enhanced green fluorescent protein (eGFP).

14. (Currently amended) A method for ~~producing differentiated neural cells~~ inducing neural cell differentiation, comprising ~~the steps of~~:

(a) ~~obtaining or generating a culture of neural stem cells or neural progenitor cells;~~

(b) ~~contacting the culture of neural stem cells or neural progenitor cells~~ a cell selected from the group consisting of a neural stem cell and a neural progenitor cell with an amount of ~~an~~ a specific ATF5 inhibitor effective to induce differentiation. ~~produce differentiated neural cells;~~
and

(c) ~~optionally, contacting the differentiated neural cells with at least one neurotrophic factor.~~

15. (Currently amended) The method of claim 14, ~~wherein steps (b)-(c) are~~ which is performed in vivo in a subject.

16. (Currently amended) The method of claim 14, ~~wherein one or more of steps (b) and (c)~~ are which is performed in vitro.

17. (Previously presented) The method of claim 16, further comprising the step of transplanting the differentiated neural cells into a subject.

18. (Currently amended) An isolated population of cells, comprising ~~the~~ a differentiated neural ~~cells~~ cell produced by the method of claim 14.

19. (Currently amended) A method for treating nervous tissue degeneration in a subject in

need of treatment, comprising the steps of:

- (a) ~~obtaining or generating~~ providing a culture comprising cells selected from the group consisting of neural stem cells and neural progenitor cells ~~of neural stem cells or neural progenitor cells~~;
- (b) ~~contacting the culture of neural stem cells or neural progenitor cells~~ with an effective amount of an ATF5 inhibitor ~~effective to produce differentiated neural cells~~ selected from the group consisting of an ATF5 antibody, siRNA, dominant negative ATF5, and antisense RNA; and
- ~~(c) — optionally, contacting the differentiated neural cells with at least one neurotrophic factor;~~
- ~~and~~
- ~~(d)~~ (c) transplanting the differentiated neural cells into the subject in an amount effective to treat the nervous tissue degeneration.

20. (Cancelled)

21-31. (Cancelled)

32. (New) A method for isolating a population of differentiated neural cells, comprising:

- (a) providing a culture comprising cells selected from the group consisting of neural stem cells and neural progenitor cells;
- (b) transfecting the culture with one or more nucleic acid, wherein said one or more nucleic acid provides an inhibitor of ATF5 and a fluorescent protein, and wherein the inhibitor is specific

for ATF5, and is in an amount effective to produce differentiated neural cells;

- (c) detecting expression of the fluorescent protein in the differentiated neural cells; and
- (d) isolating the differentiated neural cells that express the fluorescent protein.